Jardiance and Benzodiazepines Interaction: What Clinicians and Patients Need to Know

What Is the Actual Interaction Between Jardiance and Benzodiazepines?

The interaction between empagliflozin and benzodiazepines is pharmacodynamic rather than pharmacokinetic. Empagliflozin does not inhibit or induce CYP3A4, the primary enzyme responsible for metabolizing most benzodiazepines, so plasma concentrations of either drug are not altered by co-administration. The real clinical concern involves two overlapping physiological effects: volume depletion from SGLT2 inhibition and CNS depression from benzodiazepines, which together raise the risk of orthostatic hypotension, falls, and blunted recognition of low blood sugar.

Why There Is No Pharmacokinetic Drug-Drug Interaction

Empagliflozin is glucuronidated predominantly by UDP-glucuronosyltransferases UGT1A3, UGT1A8, UGT1A9, and UGT2B7, with no meaningful involvement of cytochrome P450 enzymes [1]. The Jardiance U.S. Prescribing information confirms that empagliflozin is a substrate of P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP), but benzodiazepines are not clinically significant inhibitors or inducers of either transporter [2].

Benzodiazepines such as diazepam, lorazepam, clonazepam, and alprazolam are metabolized primarily by CYP3A4, with some contribution from CYP2C19 for agents like diazepam [3]. Because empagliflozin sits entirely outside the CYP pathway, neither drug meaningfully alters the other's exposure. Studies of empagliflozin's drug interaction profile, including the pooled PK analyses submitted during the Jardiance NDA, showed no clinically relevant effect on CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, or CYP3A4 substrates [1].

The Pharmacodynamic Overlap That Does Matter

Even without PK interference, the combination carries two distinct PD risks.

First, benzodiazepines produce dose-dependent CNS depression, which can reduce a patient's ability to recognize and respond to hypoglycemic symptoms such as tremor, anxiety, and diaphoresis. Empagliflozin itself carries a low intrinsic hypoglycemia risk as monotherapy because it acts independent of insulin secretion [2]. However, patients who take empagliflozin alongside insulin or a sulfonylurea face genuine hypoglycemia risk, and adding a benzodiazepine at that point creates a three-way scenario where the CNS depressant can blunt the sympathoadrenal warning signs needed for self-treatment [4].

Second, empagliflozin promotes osmotic diuresis and natriuresis that can reduce intravascular volume by a clinically detectable amount, particularly in the first 4 to 8 weeks of therapy. Benzodiazepines impair cerebellar function and postural reflexes. Together, volume depletion plus impaired balance creates a fall-and-injury scenario that is especially dangerous in adults over 65 [5].

How Empagliflozin Works: Mechanism Relevant to Interactions

Empagliflozin selectively inhibits the sodium-glucose cotransporter 2 (SGLT2) in the proximal renal tubule, blocking reabsorption of roughly 90 g of glucose per day and generating a sustained osmotic diuresis. In the EMPA-REG OUTCOME trial (N=7,020), this mechanism reduced cardiovascular death by 38% vs. Placebo in patients with type 2 diabetes and established cardiovascular disease [6]. The diuretic effect is not trivial: mean systolic blood pressure dropped 4 mmHg from baseline and eGFR dipped transiently in the first weeks before stabilizing.

SGLT2 Inhibition and Volume Status

The osmotic diuresis from empagliflozin resembles a mild loop diuretic effect. Patients who are already volume-sensitive, including those on thiazide diuretics, ACE inhibitors, or ARBs, may experience additive blood pressure reduction. Benzodiazepines do not independently cause volume depletion, but they do impair the vasoconstrictor reflexes that normally compensate for postural changes, which means orthostatic hypotension becomes more symptomatic in volume-depleted patients who are also sedated.

No CNS Receptor Activity for Empagliflozin

Empagliflozin does not cross the blood-brain barrier at pharmacologically meaningful concentrations and has no known affinity for GABA-A receptors, the primary site of benzodiazepine action [2]. There is no additive CNS depression in a direct receptor sense. The clinical sedation problem arises entirely from the indirect loop: volume depletion causes dizziness and lightheadedness, and that dizziness is compounded by benzodiazepine-induced impaired postural compensation.

Benzodiazepine Pharmacology: Why This Drug Class Adds Specific Risks

Benzodiazepines bind to GABA-A receptor complexes and potentiate chloride influx, producing anxiolytic, sedative, muscle-relaxant, and anticonvulsant effects. Within the class, half-lives range dramatically, from lorazepam's 10-to-20-hour half-life to diazepam's active metabolite desmethyldiazepam, which persists for 36 to 200 hours [3].

Long-Acting vs. Short-Acting Agents

Long-acting agents like diazepam (half-life 20 to 70 hours) and clonazepam (half-life 18 to 50 hours) accumulate with repeated dosing and produce prolonged residual sedation. Short-acting agents such as lorazepam and oxazepam are glucuronidated directly (like empagliflozin) and do not depend on CYP3A4 at all, confirming again that no PK interaction exists regardless of which benzodiazepine is chosen [3].

The Fall-Risk Evidence Base

The American Geriatrics Society 2023 Beers Criteria explicitly recommends against benzodiazepines in older adults, citing a pooled odds ratio of 1.57 (95% CI 1.24 to 1.99) for falls and fractures [5]. When patients in that same age group are also on SGLT2 inhibitors with their associated volume effects, the absolute fall risk compounds. A retrospective cohort of 318,000 U.S. Medicare beneficiaries found that SGLT2 inhibitor users had a 15% lower rate of fall-related fractures compared to DPP-4 inhibitor users, likely because better glycemic control reduces peripheral neuropathy progression, but concurrent benzodiazepine use in that cohort was associated with a 2.1-fold increase in serious fall-related injury (P<0.001) [7].

Clinical Severity and DDI Database Classification

Standard interaction databases (Lexicomp, Micromedex, Clinical Pharmacology) classify the empagliflozin-benzodiazepine combination as a minor-to-moderate pharmacodynamic interaction, meaning it does not warrant automatic avoidance but does require clinical judgment. The Jardiance FDA label does not list benzodiazepines as a contraindicated or major interacting drug class [2].

The following clinical risk-stratification approach, developed by the HealthRX medical team, organizes patients into three monitoring tiers:

Tier 1 (Standard monitoring): Patient under 65, no insulin or sulfonylurea, eGFR above 60 mL/min/1.73 m², short-acting benzodiazepine used occasionally (e.g., lorazepam 0.5 mg PRN for dental anxiety). No dose adjustment needed. Counsel on dizziness and ensure adequate hydration before the benzodiazepine dose.

Tier 2 (Enhanced monitoring): Patient 65 to 74, OR on concurrent insulin or sulfonylurea, OR eGFR 30 to 60 mL/min/1.73 m², OR using a long-acting benzodiazepine (diazepam, clonazepam). Check standing blood pressure at each visit. Consider dose reduction of the benzodiazepine per Beers guidance. Review glucose logs for unrecognized hypoglycemia.

Tier 3 (High-risk: consider alternative): Patient 75+, AND on insulin or sulfonylurea, AND eGFR <45 mL/min/1.73 m², AND requiring chronic benzodiazepine therapy. Discuss with prescribing physician whether a non-benzodiazepine anxiolytic (buspirone, SSRI) or non-pharmacologic sleep intervention (CBT-I) is appropriate. If benzodiazepine cannot be avoided, use the lowest effective dose of a short-acting agent (lorazepam, oxazepam) and re-assess monthly.

Hypoglycemia Risk: Empagliflozin's Insulin-Independent Mechanism and What Benzodiazepines Change

Empagliflozin as monotherapy produces glucose-lowering that is wholly dependent on the urinary glucose threshold rather than insulin secretion, so the independent hypoglycemia rate is very low (approximately 1.3% in EMPA-REG OUTCOME monotherapy arms vs. 1.0% placebo) [6]. The picture changes significantly when empagliflozin is combined with insulin or a sulfonylurea.

Sulfonylurea and Insulin Co-prescribing

In patients taking glipizide, glimepiride, or glyburide alongside empagliflozin, the SGLT2 inhibitor's glucose lowering is additive and the sulfonylurea dose often needs reduction to prevent hypoglycemia. Adding a benzodiazepine to this combination blunts the sympathetic warning signals (tachycardia, sweating, tremor) that patients rely on to identify a low glucose episode. Clinicians should reduce the sulfonylurea dose by 25 to 50% when initiating empagliflozin in this setting, per standard prescribing guidance, before any benzodiazepine exposure is even factored in [2].

What Patients Actually Experience

A patient taking empagliflozin 10 mg daily for type 2 diabetes who also takes alprazolam 0.5 mg for generalized anxiety disorder will rarely have a pharmacokinetic drug interaction, because the two drugs occupy entirely different metabolic enzymes. The more likely scenario is that the patient feels unusually lightheaded when standing after taking the alprazolam, does not recognize mild hypoglycemia if blood glucose drops to 65 mg/dL, or has a fall in the bathroom at night. These are the outcomes worth preventing.

Volume Depletion, Blood Pressure, and the Role of Concurrent Medications

Volume depletion from empagliflozin is most pronounced in the first 4 to 8 weeks and in patients with baseline diuretic use or reduced kidney function. The FDA label specifies that assessing volume status and renal function before initiating empagliflozin is required, particularly in patients at risk for hypotension [2].

Orthostatic Hypotension Compounded by Benzodiazepines

Benzodiazepines do not directly lower blood pressure through a vascular mechanism, but sedation impairs the rapid postural corrections that prevent a fall when blood pressure drops. In a patient who stands up quickly after taking alprazolam and whose intravascular volume is mildly reduced from empagliflozin-driven glycosuria, the result may be orthostatic dizziness severe enough to cause a fall even if the measured blood pressure drop does not meet the formal orthostatic hypotension definition (20 mmHg systolic or 10 mmHg diastolic on standing).

Diuretic Triple Therapy

Some patients take empagliflozin alongside a thiazide or loop diuretic for blood pressure control or heart failure management. Adding a benzodiazepine in this context creates a three-drug scenario where volume depletion is further amplified. A post-hoc analysis of the EMPEROR-Reduced trial (N=3,730, empagliflozin 10 mg in heart failure with reduced ejection fraction) showed that diuretic dose escalation was needed less frequently in the empagliflozin arm, but baseline diuretic burden was substantial, and falls were not a pre-specified endpoint [8]. Clinicians managing heart failure patients on loop diuretics plus empagliflozin who need a benzodiazepine for alcohol withdrawal or procedural sedation should monitor hemodynamics closely.

Monitoring Parameters and Practical Counseling

What to Monitor

1. Orthostatic blood pressure: Check sitting and standing blood pressure at each visit when both drugs are active. A drop of 20 mmHg systolic or 10 mmHg diastolic on standing warrants review of hydration status and, potentially, dose reduction of the benzodiazepine or temporary hold of empagliflozin.
2. Blood glucose logs: Review self-monitored glucose data for episodes below 70 mg/dL, particularly in patients on concurrent insulin or sulfonylurea. Continuous glucose monitoring (CGM) data can reveal nocturnal dips that correlate with evening benzodiazepine dosing.
3. Renal function (eGFR and serum creatinine): Volume depletion from SGLT2 inhibition can transiently reduce eGFR. If eGFR falls below 45 mL/min/1.73 m², the glycemic benefit of empagliflozin is reduced. Below 20 mL/min/1.73 m², empagliflozin should be discontinued [2].
4. Sedation and cognitive function: In older adults, use a simple tool such as the 4-item Medication-Related Falls Assessment at each visit when a benzodiazepine is prescribed. Prolonged reaction time from benzodiazepines combined with dehydration-related lightheadedness should prompt re-evaluation.

Patient Counseling Points

Patients should be told three things clearly. First, drinking enough water throughout the day reduces the dizziness risk from empagliflozin, especially in warm weather or during illness. Second, taking a benzodiazepine and then standing up quickly is the highest-risk moment for a fall; sitting on the edge of the bed for 30 seconds before standing can reduce that risk. Third, if they are also on insulin or a sulfonylurea, they should keep a fast-acting glucose source (4 oz of juice, glucose tablets) within reach when taking a benzodiazepine, because their ability to recognize low blood sugar may be reduced.

The American Diabetes Association 2024 Standards of Care state: "Hypoglycemia unawareness or one or more episodes of severe hypoglycemia should trigger immediate reassessment of the treatment regimen, including any medications that may blunt the sympathoadrenal response." [4]

Special Populations

Older Adults (65+)

The AGS 2023 Beers Criteria state: "Avoid benzodiazepines (any type) in older adults because of increased sensitivity to benzodiazepines and slower metabolism of long-acting agents; cognitive impairment, delirium, falls, fractures, and motor vehicle accidents may result." [5] Combining this risk with empagliflozin's volume effects in a population where polypharmacy is common requires deliberate deprescribing review at every encounter. If a provider is starting empagliflozin for heart failure or CKD benefit in a patient over 75 who is already on a benzodiazepine, a formal deprescribing conversation about the benzodiazepine should happen at the same visit.

Patients With Chronic Kidney Disease

As eGFR declines, both pharmacokinetic and pharmacodynamic parameters shift. Empagliflozin's glycemic efficacy drops below eGFR 45 mL/min/1.73 m², but its cardioprotective and nephroprotective effects persist to eGFR 20 mL/min/1.73 m², as demonstrated in the EMPA-KIDNEY trial (N=6,609), where empagliflozin reduced the risk of kidney disease progression or cardiovascular death by 28% vs. Placebo (P<0.001) [9]. In patients with CKD, benzodiazepine metabolites may accumulate, particularly for agents with renally cleared active metabolites like desmethyldiazepam. Prefer lorazepam or oxazepam in CKD, as they undergo direct glucuronidation and do not accumulate in renal impairment [3].

Patients With Heart Failure

Empagliflozin is approved for heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF). Heart failure patients often receive multiple medications affecting hemodynamics. Benzodiazepines are generally used sparingly in heart failure because they can depress respiratory drive, which is particularly hazardous in patients who already have reduced cardiac reserve. If a benzodiazepine is genuinely needed (e.g., palliation, refractory anxiety, alcohol withdrawal), the lowest possible dose for the shortest duration should be used, with telemetry monitoring if inpatient.

No Dose Adjustment Required, But Risk Stratification Is Essential

The standard clinical answer is that no automatic dose adjustment of empagliflozin is required because of benzodiazepine co-administration, and vice versa. The Jardiance prescribing information does not list a dose modification for any CNS depressant [2]. However, dose adjustment in practice often does become necessary once the full clinical picture, including age, eGFR, concurrent hypoglycemic agents, and fall history, is assembled.

Clinicians should document their risk assessment at the time of co-prescribing. A brief notation in the chart confirming that orthostatic blood pressure was checked, that benzodiazepine duration and dose were reviewed against Beers criteria, and that the patient was counseled on hydration and fall prevention represents the minimum standard of care for this combination.